Hidden Gene Triggers Fatty Liver Disease

A single hidden gene mutation can silently trigger fatty liver disease in people without obesity or diabetes, upending decades of medical assumptions.

Story Snapshot

Mayo Clinic researchers pinpointed a rare MET gene variant as a direct cause of MASLD in a family lacking typical risk factors.
The mutation disrupts liver fat processing and repair, appearing in about 1% of MASLD cases in Mayo’s massive Tapestry study.
This discovery reveals monogenic drivers within common diseases, pushing precision medicine forward.
Experts predict broader genetic screening and targeted therapies to curb rising cirrhosis rates.
Validation came from sequencing over 20,000 genes and analyzing data from more than 100,000 participants.

The Patient Case That Cracked the Code

A woman and her father developed metabolic dysfunction-associated steatotic liver disease, now MASLD, without diabetes, high cholesterol, or obesity. Doctors at Mayo Clinic’s Center for Individualized Medicine sequenced over 20,000 genes in their genomes. They identified a novel variant in the MET gene, absent from public databases. This gene normally regulates liver repair and fat metabolism. The mutation blocked fat processing, causing dangerous buildup. Collaboration with Medical College of Wisconsin confirmed its biological impact.

MET Gene’s Critical Role Exposed

The MET gene directs liver cells to metabolize fats and heal damage. Researchers found the variant halted these functions, leading to steatohepatitis, or MASH, MASLD’s severe form. Unlike typical cases tied to metabolic syndrome, this stood alone. Validation occurred through Mayo’s Tapestry study, analyzing germline DNA from over 100,000 U.S. adults. Among roughly 4,000 with MASLD, MET variants appeared in 1%, with 18% in the key functional region. Publication in Hepatology solidified the findings.

Paradigm Shift in MASLD Understanding

MASLD affects one-third of adults worldwide, with MASH poised to drive most cirrhosis and transplants. Doctors long blamed combined genetics and lifestyle factors like insulin resistance. This case proves rare single variants can suffice, hidden among common diseases. Mayo’s Program for Rare and Undiagnosed Diseases, launched in 2019, aided over 3,200 patients. Tapestry, ongoing since then, sequences exomes to reveal such drivers. Precedents exist in genetic liver conditions like hemochromatosis, but not for MASLD.

Filippo Pinto e Vairo, Medical Director of the rare diseases program, stated the find opens doors to rare variants fueling epidemics and new therapies. Konstantinos Lazaridis, Center Director, noted it could impact hundreds of thousands, underscoring family studies and big data. Raul Urrutia from Wisconsin affirmed individualized medicine unmasks these causes.

Mayo Clinic discovers rare gene mutation that causes fatty liver diseasehttps://t.co/F6y1JNB6Ce pic.twitter.com/Ys8nKnpZwD

— Science Academy (@Academ18Academy) March 8, 2026

Immediate and Future Health Impacts

Short-term, unexplained MASLD cases now warrant MET screening and family testing. Long-term, MET-targeted drugs could halt progression, reclassifying cases as monogenic. Millions might benefit, given 1% prevalence hints at vast numbers. Economic savings follow from averting cirrhosis; precedents like lysosomal acid lipase deficiency show half advance in three years without intervention. Socially, it eases burdens on aging populations. Hepatology integrates genomics, mirroring tests for alpha-1 or Wilson disease.